Chime Financial, Inc. is a San Francisco-based financial technology company that provides digital consumer banking and payment solutions in the United States and internationally. Founded in 2012 and publicly listed on Nasdaq in June 2025, the company operates a mobile-first banking platform built in partnership with third-party banks. Chime’s product suite spans fee-free checking and debit cards, high-yield savings, credit-building tools, and liquidity products such as SpotMe, MyPay (earned wage access), and Instant Loans. More recently, the company introduced Chime Prime, a premium membership tier, and Chime Invest, which offers managed portfolios and commission-free self-directed investing. Investors follow the stock for its member growth, monetization trends, and path toward sustained profitability in the competitive U.S. digital banking market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, CHYM shares advanced approximately 44%, climbing from a closing price of about $22.99 on July 31, 2026, to $33.11 on August 31, 2026. The most dramatic move occurred in early August, when the stock jumped sharply following its second-quarter earnings release, briefly touching an intraday high of $33.41. The broader quarterly trend was even more pronounced. From around $17.50 in early June 2026, the stock gained roughly 89% through the end of August. This rally followed a period of weakness in which shares hit a 52-week low of $16.44 on June 10, 2026, before a steady recovery through July and an acceleration in August. The result was a sustained uptrend that lifted the stock from multi-month lows toward its highest levels in about a year. To put the recent move in perspective, I reviewed trend signals with Tickeron’s AI Trend Prediction Engine.
The primary catalyst was Chime's second-quarter 2026 earnings report, released on August 5, 2026. The company posted revenue of $669.8 million, up 27% year over year, and reported GAAP net income of $28 million—its second consecutive quarter of profitability. Adjusted earnings per share of $0.07 handily beat consensus expectations for a small loss, while adjusted EBITDA reached $102 million at a 15% margin, up 12 percentage points year over year. Management also raised its full-year guidance, projecting revenue of $2.725 billion to $2.745 billion (25% to 26% growth) and adjusted EBITDA of $465 million to $475 million. Active members grew 20% year over year to 10.4 million, and average revenue per active member (ARPAM) rose 6% to $260. Strong momentum in Chime Prime—whose members generate more than double the ARPAM of the average member—along with a 36% increase in transaction profit reinforced the profitability narrative and drove the post-earnings surge.
The quarterly rally reflected a broader shift in investor sentiment toward Chime's profitability trajectory. After declining into a June 2026 low, the stock began recovering as the company demonstrated that its operating model could convert strong member growth into expanding margins. The rollout of Chime Prime in April, the launch of Chime Invest in July, and accelerating liquidity-product growth all contributed to a more constructive outlook. Supporting factors included tripling MyPay transaction profit to $73 million, nearly 70% sequential growth in Instant Loan originations to $300 million, and a new $500 million warehouse facility with Goldman Sachs to fund lending growth. Enterprise momentum also improved, highlighted by a Chime Workplace agreement with Allied Universal. These developments, combined with cost-efficiency initiatives, underpinned the stock's roughly 89% advance over the quarter.
Looking ahead, investors will likely monitor several factors. Rewards costs tied to Chime Prime's cash-back program and potential shifts in loss rates as MyPay limits expand and lending products scale will be important to profitability trends. The company's transition to a permanent CFO following the departure of Matthew Newcomb is another execution-related item to track. Continued member growth, ARPAM expansion, and adoption of Chime Invest and the planned revolving line of credit will shape the revenue outlook. Enterprise partnerships, including the Allied Universal rollout, could influence member acquisition in 2027. Macroeconomic conditions affecting consumer spending and credit quality, along with regulatory developments in digital banking and earned wage access, also remain relevant. Investors should watch upcoming earnings and guidance updates to assess whether the recent momentum is sustained. I also examined pattern activity with Tickeron’s AI Pattern Search Engine for additional context.
In my own research process, I often turn to Tickeron’s AI Trading Bots to review automated strategies across thousands of tickers. The platform highlights top-performing bots with varying timeframes and approaches, which helps me quickly evaluate rules-based options that align with current market conditions without manually screening every possibility. This adds a useful layer of data-driven perspective to traditional analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CHYM saw its Momentum Indicator move above the 0 level on September 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator turned positive. In of the 19 cases, the stock moved higher in the following days. The odds of a move higher are at .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHYM advanced for three days, in of 61 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 43 cases where CHYM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for CHYM moved out of overbought territory on September 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for CHYM turned negative on August 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHYM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CHYM broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.107) is normal, around the industry mean (28.665). P/E Ratio (6.291) is within average values for comparable stocks, (78.353). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.664). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (5.313) is also within normal values, averaging (76.156).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows